

Althea Achieves 1,000 Patient Milestone

Investment Highlights:


- 1,000 patients have now been prescribed Althea medicinal cannabis products in Australia
- 185 Healthcare Professionals have prescribed Althea medicinal cannabis
- Althea is averaging more than 11 new patients per business day, including 227 additional patients in May
- Althea has achieved the 1,000 patient milestone five months ahead of schedule

14 June 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to provide the following update regarding the uptake of its medicinal cannabis products in Australia.

The Company is excited to announce that it has achieved the 1,000-patient milestone, a more than 53% increase on the 651 patients reported on 29 April 2019.


Althea welcomed 227 new patients in the month of May, and the Company is now averaging more than 11 new patients per business day. The milestone was achieved five months ahead of the Company's previously stated goal of having its products prescribed to 1,000 patients by November 2019 [ASX Announcement: November 2, 2018].

Chart 1: Patient Growth



In addition to Althea passing the 1,000-patient mark and 227 patients in a single month, there are now 185 Australian Healthcare Professionals ('HCPs') who have prescribed Althea's products. The Company expects to increase the number of Althea prescribers to 200, by month's end.

Chart 2: HCP Growth



The rapid uptake of Althea's products is being driven by the Company's two-pronged strategy comprised of an on-the-ground Medical Science Liaison team and *Althea Concierge*, the Company's proprietary web-based platform which greatly reduces application times for HCP's looking to prescribe medicinal cannabis.

Althea CEO & Managing Director Josh Fegan said: "Reaching the 1,000 patient milestone less than nine months after listing on the ASX is a major achievement for Althea. I'd like to thank the whole team for working hard to make this happen and reiterate my appreciation for the ongoing support of our shareholders. With our on-the-ground team and unique *Althea Concierge* platform, Althea is able to educate HCPs about the benefits of our products and streamline the entire medicinal cannabis prescription process."

Following the success of *Althea Concierge* in Australia, and with a clear competitive advantage, the Company recently announced the launch of *Althea Concierge UK*. The United Kingdom is in an emerging market with significant potential, including an estimated treatable population of up to 2.9 million patients¹.

Mr Fegan added: "This latest milestone both reinforces and validates Althea's strong patient and HCP focussed approach, putting us in a commanding position in Australia. The plan is to replicate our early success in the UK where the full suite of Althea resources, including both the MEDIC and *Althea Concierge* platforms, have now been deployed. I look forward to providing an update on our progress in the UK in the near future."

Ends

¹ Source: Prohibition Partners, *The European Cannabis Report*, January 2019, 4th Edition, p.83.

For further information, please contact:

Althea

Josh Fegan
CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.life

Media Enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities
M: 03 8633 9834
E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life